Cardiff Oncology, Inc. (CRDF)

[CHM_760]

Leerink Partners Starts TrovaGene (TROV) at Outperform - $9 PT
August 14, 2015 7:05 AM EDT

Leerink Partners initiates coverage on TrovaGene (NASDAQ: TROV) with a Outperform rating and a price target of $9.00.

Analyst Dan Leonard commented, "We are initiating coverage of San Diego, CA-based Trovagene (TROV) with an Outperform rating and a $9 price target. TROV is an early stage pure play in the cancer liquid biopsy market, a market with the potential in our view to be the largest in molecular diagnostics."
The analyst said the market opportunity could be large. "TROV sits at the forefront of the opportunity to use nextgen sequencing (NGS) to detect cancer markers in biofluids (i.e., liquid biopsy). We believe this type of testing at minimum could complement tissue testing and will likely prove useful in multiple circumstances. While market opportunity assessments for liquid biopsy vary widely, depending on the use case, one can readily envision a market totaling north of $10B long term."